NF1
2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Angeles TherapeuticsPoly ICLC
AmgenImlygic
MedtronicINFUSE Bone Graft
Clinical Trials (3)
Total enrollment: 18 patients across 3 trials
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
Start: Feb 2022Est. completion: Nov 20243 patients
Phase 2Terminated
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Start: Feb 2026Est. completion: Dec 202710 patients
Phase 1Recruiting
A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)
Start: Mar 2016Est. completion: Jun 20205 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 18 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.